Pharmaceutical manufacturer Laurus Labs said that its has entered into a strategic partnership agreement with United Nations’ The Global Fund to sell a generic version of Viiv Healthcare’s dolutegravir (DTG) tablets in the Sub-Saharan countries for three years. Read More
